非布司他进入医保了吗？

In February 2009, it was approved by the US FDA for the treatment of gout in adults.

In 2013, febuxostat was launched in China. Has febuxostat entered the medical insurance?

According to Medical Companion Travel, febuxostat has been included in the national medical insurance, and patients can use medical insurance for reimbursement!

Febuxostat is a potent non-purine selective inhibitor of xanthine oxidase (XO). It achieves the therapeutic effect of reducing serum uric acid by selectively inhibiting xanthine oxidase. Uric acid is the end product of purine metabolism and is produced in the cascade reaction of hypoxanthine → xanthine → uric acid. Each step of the conversion is catalyzed by xanthine oxidase.

Febuxostat has been shown to effectively inhibit both the oxidized and reduced forms of xanthine oxidase. Febuxostat at therapeutic concentrations does not inhibit other enzymes involved in purine or pyrimidine metabolism, namely guanine deaminase, hypoxanthine guanine phosphoribosyltransferase, orotate phosphoribosyltransferase, orotate monophosphate decarboxylase, or purine nucleoside phosphorylase.

Obvious advantages of Febus:

1. Few side effects

Allopurinol may cause hypersensitivity reactions, or even very serious drug rashes that may lead to patient death. Although febuxostat may also cause drug rash, it is significantly less severe than allopurinol.

2. More suitable for patients with renal insufficiency and kidney stones

Febuxostat is mainly metabolized in the liver. A considerable number of gout patients suffer from renal insufficiency or kidney stones. In this case, Febuxostat is a very good choice.

Therefore, febuxostat is safer than allopurinol and is more suitable for patients with renal insufficiency and kidney stones.

It has definite efficacy and is safer than allopurinol. It is more suitable for patients with renal insufficiency and kidney stones. However, you still need to pay attention to skin rash and liver and kidney function during medication.

Recommended related hot articles: /newsDetail/74715.html